First Clinical Trial of Lung Cancer Vaccine Begins in Seven Countries Worldwide

With the commencement of the clinical trial for the first lung cancer vaccine in seven countries worldwide, the first patient in the UK received an injection of this vaccine. This vaccine, named 'BNT 116' and developed by BioNTech, is designed to eliminate the most common form of lung cancer and prevent its recurrence. Doctors and experts have welcomed the potential of this new vaccine to be 'pioneering' in saving the lives of thousands. Lung cancer claims the lives of approximately 1.8 million people worldwide each year, and the survival rate for individuals with advanced forms of the disease, where tumors have spread, is particularly low. Specialists are now testing this new vaccine, which instructs the body to hunt down and destroy cancer cells, thereby preventing the recurrence of the disease. In the first phase of the vaccine trial, research centers have been established in seven countries: the UK, the United States, Germany, Hungary, Poland, Spain, and Turkey. In the UK, six centers have been set up in England and Wales for this purpose. According to reports, this vaccine will be administered to 130 patients at various stages of lung cancer. The goal of this vaccine is to enhance the individual's immune system to combat cancer, unlike chemotherapy, while not harming healthy body cells. This is not the first time a vaccine has been tested to combat cancer. In June of this year, the National Health Service of England announced that it had begun clinical trials of personalized cancer vaccines, whereby each cancer patient would receive a vaccine tailored to their specific tumor.